MAGEA4 and synovial sarcoma: Many trials examining immunotherapy have been conducted regardless of the sarcoma subtype, with promise in synovial sarcoma.[21,22] Only 1 report showed that NY-ESO-1 was positive in 14.3% of DT cases.[23] In the current study, all patients tested positive for both NY-ESO-1 and MAGE-A4, and the cell-positivity rates were relatively high (38% and 63%, respectively).